These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38489662)

  • 61. Causes of Mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol Related Fatty Liver Disease (AFLD).
    Johnston MP; Patel J; Byrne CD
    Curr Pharm Des; 2020; 26(10):1079-1092. PubMed ID: 32003662
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Nonalcoholic Fatty Liver Disease is Associated with Increased Carotid Intima-Media Thickness in Type 1 Diabetic Patients.
    Zhang L; Guo K; Lu J; Zhao F; Yu H; Han J; Bao Y; Chen H; Jia W
    Sci Rep; 2016 May; 6():26805. PubMed ID: 27226159
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis.
    Fang L; Li J; Zeng H; Liu J
    Prim Care Diabetes; 2024 Jun; 18(3):268-276. PubMed ID: 38555202
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Association between nonalcoholic fatty liver disease and subclinical atherosclerosis: a cross-sectional study on population over 40 years old.
    Zheng J; Zhou Y; Zhang K; Qi Y; An S; Wang S; Zhao X; Tang YD
    BMC Cardiovasc Disord; 2018 Jul; 18(1):147. PubMed ID: 30012085
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Association of serum ferritin with non-alcoholic fatty liver disease: a meta-analysis.
    Du SX; Lu LL; Geng N; Victor DW; Chen LZ; Wang C; Yue HY; Xin YN; Xuan SY; Jin WW
    Lipids Health Dis; 2017 Dec; 16(1):228. PubMed ID: 29197393
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Gastrointestinal cancers in lean individuals with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Souza M; Diaz I; Barchetta I; Mantovani A
    Liver Int; 2024 Jan; 44(1):6-14. PubMed ID: 37833849
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Heritability of non-alcoholic fatty liver disease and association with abnormal vascular parameters: a twin study.
    Tarnoki AD; Tarnoki DL; Bata P; Littvay L; Osztovits J; Jermendy G; Karlinger K; Lannert A; Preda I; Kiss RG; Molnar AA; Garami Z; Baffy G; Berczi V
    Liver Int; 2012 Sep; 32(8):1287-93. PubMed ID: 22651705
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Uncovering the Cardiovascular Threat: A Comprehensive Examination of Liver Fibrosis and Subclinical Atherosclerosis in Non-alcoholic Fatty Liver Disease.
    Sharma N; Chakole S; Wandile B
    Cureus; 2023 Oct; 15(10):e46946. PubMed ID: 38021670
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Nonalcoholic fatty liver disease and vascular disease: state-of-the-art.
    Fargion S; Porzio M; Fracanzani AL
    World J Gastroenterol; 2014 Oct; 20(37):13306-24. PubMed ID: 25309067
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Hepatic artery resistive index (HARI) and non-alcoholic fatty liver disease (NAFLD) fibrosis score in NAFLD patients: cut-off suggestive of non-alcoholic steatohepatitis (NASH) evolution.
    Tana C; Tana M; Rossi S; Silingardi M; Schiavone C
    J Ultrasound; 2016 Sep; 19(3):183-9. PubMed ID: 27635163
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Fatty liver is a good indicator of subclinical atherosclerosis risk in obese children and adolescents regardless of liver enzyme elevation.
    Akın L; Kurtoglu S; Yikilmaz A; Kendirci M; Elmalı F; Mazicioglu M
    Acta Paediatr; 2013 Mar; 102(3):e107-13. PubMed ID: 23190373
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Assessment of the co-incidence between non alcoholic fatty liver disease and carotid atherosclerosis.
    El-Sayed SA; El-Folly RF; Ahmed AM
    J Egypt Soc Parasitol; 2014 Apr; 44(1):187-95. PubMed ID: 24961024
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Association of Serum Bilirubin With Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Liang C; Yu Z; Bai L; Hou W; Tang S; Zhang W; Chen X; Hu Z; Duan Z; Zheng S
    Front Endocrinol (Lausanne); 2022; 13():869579. PubMed ID: 35937795
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Association of nonalcoholic fatty liver disease and carotid media-intima thickness: A systematic review and a meta-analysis.
    Khoshbaten M; Maleki SH; Hadad S; Baral A; Rocha AV; Poudel L; Abdshah A
    Health Sci Rep; 2023 Sep; 6(9):e1554. PubMed ID: 37701352
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis.
    Komolafe O; Buzzetti E; Linden A; Best LM; Madden AM; Roberts D; Chase TJ; Fritche D; Freeman SC; Cooper NJ; Sutton AJ; Milne EJ; Wright K; Pavlov CS; Davidson BR; Tsochatzis E; Gurusamy KS
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD013157. PubMed ID: 34280304
    [TBL] [Abstract][Full Text] [Related]  

  • 76.
    Zhao W; Mori H; Tomiga Y; Tanaka K; Perveen R; Mine K; Inadomi C; Yoshioka W; Kubotsu Y; Isoda H; Kuwashiro T; Oeda S; Akiyama T; Zhao Y; Ozaki I; Nagafuchi S; Kawaguchi A; Aishima S; Anzai K; Takahashi H
    Genes (Basel); 2022 Jul; 13(7):. PubMed ID: 35886046
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Circulating tumor necrosis factor-α levels in non-alcoholic fatty liver disease: A systematic review and a meta-analysis.
    Potoupni V; Georgiadou M; Chatzigriva E; Polychronidou G; Markou E; Zapantis Gakis C; Filimidou I; Karagianni M; Anastasilakis D; Evripidou K; Ftergioti A; Togkaridou M; Tsaftaridis N; Apostolopoulos A; Polyzos SA
    J Gastroenterol Hepatol; 2021 Nov; 36(11):3002-3014. PubMed ID: 34289181
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Blood Endotoxin Levels as Biomarker of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis.
    Soppert J; Brandt EF; Heussen NM; Barzakova E; Blank LM; Kuepfer L; Hornef MW; Trebicka J; Jankowski J; Berres ML; Noels H
    Clin Gastroenterol Hepatol; 2023 Oct; 21(11):2746-2758. PubMed ID: 36470528
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up.
    Fracanzani AL; Tiraboschi S; Pisano G; Consonni D; Baragetti A; Bertelli C; Norata D; Valenti L; Grigore L; Porzio M; Catapano A; Fargion S
    Atherosclerosis; 2016 Mar; 246():208-13. PubMed ID: 26803429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.